Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol

Experimental and Therapeutic Medicine

Volumn 1, Issue 3, 2010, Pages 531-536

  Cruz, Pamela ^a   Torres, Cristian ^b   Ramírez, María Eugenia ^a   Epuñán, María José ^a   Valladares, Luis Emilio ^a   Sierralta, Walter Daniel ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

27 Hydroxycholesterol; Epidermal growth factor receptor 2; Estradiol; ICI 182,780; MCF7 Cells; Proliferation; Simvastatin

Indexed keywords

26 HYDROXYCHOLESTEROL; ALPHA FETOPROTEIN; ALPHA FETOPROTEIN DERIVED CYCLIC NANOPEPTIDE; ESTRADIOL RECEPTOR; FULVESTRANT; PEPTIDE DERIVATIVE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INFILTRATION; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MACROPHAGE; MITOGENICITY;

EID: 77956221591     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000084     Document Type: Article

References (33)

1. Russo IHand Russo J: Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61, 1998.
2. Conzen SD: Nuclear receptors and breast cancer. Mol Endocrinol 22: 2215-2228, 2008.
3. Fox EM, Andrade J and Shupnik MA: Novel actions of estrogen to promote proliferation integration of cytoplasmic and nuclear pathways. Steroids 74: 622-627, 2009.
4. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JAand Katzenellenbogen BS: Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol Endocrinol 22: 2116-2127, 2008.
5. He J, Cheng Q and Xie W: Minireview: nuclear receptor-controlled steroid hormone synthesis and metabolism. Mol Endocrinol 24: 11-21, 2010.
6. Sasano H, Suzuki T, Nakata Tand Moriya T: New development in intracrinology of breast carcinoma. Breast Cancer 13: 129-136, 2006.
7. Arpino G, Weichmann L, Osborne CK and Schiff R: Crosstalk between the estrogen receptor and the HERtyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233, 2008.
8. Hall JMand McDonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 5: 343-357, 2005.
9. Shelly W, Draper MW, Krishnan V, Wong Mand Jaffe RB: Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 63: 163-181, 2008.
10. Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW and Mangelsdorf DJ: 27-Hydroxycholesterol is an endogenous SERMthat inhibits the cardiovascular effects of estrogens. Nature Med 13: 1185-1192, 2007.
11. DuSell CD, Umetani M, Shaul PW, Mangelsdorf DJ and McDonnell DP: 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22: 65-77, 2008.
12. Brown AJ and Jessup W: Oxysterols and atherosclerosis. Atherosclerosis 142: 1-28, 1999.
13. Hirayama T, Mizokami Y, Honda A, Homma Y, Ikegami T, Saito Y, Miyazaki Tand Matsuzaki Y: Serum concentration of 27-hydroxycholesterol predicts the effects of high-cholesterol diet on plasma LDLcholesterol level. Hepatol Res 39: 149-156, 2009.
14. Babiker A, Dzeletovic S, Wiklund B, Pettersson N, Salonen J, Nyyssönen K, Eriksson M, Diczfalusy Uand Björkhem I: Patients with atherosclerosis may have increased circulating levels of 27-hydroxycholesterol and cholestenoic acid. Scand J Clin Lab Invest 65: 365-375, 2005.
15. Hultén LM, Lindmark H, Diczfalusy U, Björkhem I, Ottosson M, Liu Y, Bondjers Gand Wiklund O: Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNAin human monocyte-derived macrophages. J Clin Invest 97: 461-468, 1996.
16. Olkkonen VMand Hynynen R: Interactions of oxysterols with membranes and proteins. Mol Aspects Med 30: 123-133, 2009.
17. Lemaire-Ewing S, Prunet C, Montange T, Vejux A, Berthier A, Bessede G, Corcos L, Gambert P, Neel Dand Lizard G: Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol 21: 97-114, 2005.
18. Riendeau V and Garenc C: Effect of 27-hydroxycholesterol on survival and death of human macrophages and vascular smooth muscle cells. Free Radic Res 43: 1019-1028, 2009.
19. Li T, Chen W and Chiang JY: PXRinduces CYP27A1 and regulates cholesterol metabolism in the intestine. J Lipid Res 48: 373-384, 2007.
20. Oyama T, Miyashita Y, Kinoshita K, Watanabe H, Shirai K and Yagima T: Effect of deposited lipids in atheromatous lesions on the migration of vascular smooth muscle cells. J Atheroscler Thromb 9: 109-113, 2002.
21. Kummerow FA, Mahfouz MM, Zhou Q and Cook LS: 27-Hydroxycholesterol causes remodeling in endothelial cell membrane lipid composition comparable to remodeling in the failed vein grafts of CABGpatients. Life Sci 78: 958-963, 2006.
22. Lange Y, Ory DS, Ye J, Lanier MH, Hsu FF and Steck TL: Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoAreductase. J Biol Chem 283: 1445-1455, 2008.
23. Sierralta WD, Epuñán MJ, Reyes JM, Valladares LE, Andersen TT, Bennett JA, Jacobson HIand Pino AM: Apeptide derived from α-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture. Oncol Rep 19: 229-235, 2008.
24. Sierralta WD, Epuñán MJ, Reyes JM, Valladares LE and Pino AM: Acyclic nonapeptide derived from alpha-fetoprotein inhibits the estradiol-induced proliferation of mammary tumor cells in culture through the modulation of p21. Adv Exp Med Biol 617: 463-468, 2008.
25. Torres C, Antileo E, Epuñán MJ, Pino AM, Valladares LE and Sierralta WD: Acyclic peptide derived from α-fetoprotein inhibits the proliferative effects of the epidermal growth factor and estradiol in MCF7 cells. Oncol Rep 19: 1597-1603, 2008.
26. Torres CG, Pino AMand Sierralta WD: Acyclized peptide derived from α-fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep 21: 1397-1404, 2009.
27. DuSell CDand McDonnell DP: 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. Trends Pharmacol Sci 29: 510-514, 2008.
28. Lange Y, Steck TL, Ye J, Lanier MH, Molugu V and Ory D: Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J Lipid Res 50: 1881-1888, 2009.
29. Steele RJ, Eremin O, Brown Mand Hawkins RA: Ahigh macrophage content in human breast cancer is not associated with favourable prognostic factors. Br J Surg 71: 456-458, 1984.
30. Javitt NB: 25R,26-Hydroxycholesterol revisited: synthesis, metabolism and biologic roles. J Lipid Res 43: 665-670, 2002.
31. Chen W, Chen G, Head DL, Mangelsdorf DJ and Russell DW: Enzymatic reduction of oxysterols impairs LXRsignaling in cultured cells and the livers of mice. Cell Metab 5: 73-79, 2007.
32. Vedin LL, Lewandowski SA, Parini P, Gustafsson JÅ and Steffensen KR: The oxysterol receptor LXRinhibits proliferation of human breast cancer cells. Carcinogenesis 30: 575-579, 2009.
33. Culhane AC and Howlin J: Molecular profiling of breast cancer: transcriptomic studies and beyond. Cell Mol Life Sci 64: 3185-3200, 2007.